Sagimet Biosciences

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel fatty acid synthase (FASN) inhibitors. Their lead product candidate, denifanstat, is an oral, once-daily pill designed to treat dysfunctional metabolic pathways in diseases stemming from the overproduction of the fatty acid palmitate. These diseases include metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), acne, and certain types of cancer.

Sagimet is currently conducting clinical trials for denifanstat in NASH, acne, and glioblastoma multiforme (GBM) in China. The company is also investigating the use of denifanstat in other cancer types, including metastatic castration-resistant prostate cancer and hepatocellular carcinoma. Sagimet's innovative approach targets multiple drivers of disease by inhibiting FASN, an enzyme responsible for lipid synthesis, and has the potential to transform treatment options for a range of metabolic and oncologic conditions.

Sagimet Biosciences does not mention any specific job flexibility options on its website or in its job postings. NONE

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel fatty acid synthase (FASN) inhibitors to address dysfunctional metabolic pathways in diseases like metabolic dysfunction-associated steatohepatitis (MASH), acne, and select forms of cancer. Their lead product candidate, denifanstat, is an oral, once-daily pill designed to target FASN overactivity, which plays a key role in the overproduction of palmitate, a saturated fatty acid implicated in these diseases. Sagimet's mission is to advance denifanstat and other FASN inhibitors through clinical development and commercialization, ultimately improving the lives of patients suffering from these challenging conditions.

Sagimet Biosciences promotes a culture of innovation, collaboration, and dedication to advancing therapies for metabolic disorders. The company values its employees and encourages a culture of open communication and teamwork. The emphasis is on scientific rigor and a passion for improving patient outcomes, creating a dynamic environment where individuals can contribute to the development of life-changing treatments.

Sagimet Biosciences is committed to building a diverse, equitable, and inclusive workplace, recognizing the value of a variety of perspectives and backgrounds. The company strives to foster a culture of respect, belonging, and opportunity for all, aiming to attract and retain talent from diverse communities. While the website lacks specific details about initiatives, policies, or programs in place, Sagimet's dedication to DEI is evident in its commitment to creating a welcoming environment where all employees feel valued and empowered.